Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Clinical trial NCT01331824 · TERMINATED
Trial details
- NCT number
- NCT01331824
- Sponsor
- Matthew Galsky
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2014-07-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.